API source — 17 things I got wrong before I got it right
API source — 17 things I got wrong before I got it right, and I am aware this is a minority view on this board.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
a 503B has to register and report, so there is a paper trail to ask for
the label on a compounded vial is a legal document, read it
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Kept the label from every vial.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
salt forms are the recurring argument and the answer is boring
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
compounded is not generic, there is no equivalence claim
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
[removed by moderator]
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
- 1A 503A pharmacy compounds for an identified patient against a prescription.…7 comments in this branch · started by u/elin_ferrari